Acute soman poisoning in primates neither pretreated nor receiving immediate therapy: value of gacyclidine (GK-11) in delayed medical support.
Organophosphorus (OP) nerve agents are still used as warfare and terrorism compounds. Classical delayed treatment of victims of organophosphate poisoning includes combined i.v. administration of a cholinesterase reactivator (an oxime), a muscarinic cholinergic receptor antagonist (atropine) and a benzodiazepine anticonvulsant (diazepam). The objective of this study was to evaluate, in a realistic setting, the therapeutic benefit of administration of GK-11 (gacyclidine), an antiglutamatergic compound, as a complement to the above therapy against organophosphate poisoning. Gacyclidine was injected (i.v.) in combination with atropine/diazepam/pralidoxime at man-equivalent doses after a 45- or 30-min latency period to intoxicated primates (2 LD50). The effects of gacyclidine on the animals' survival, electroencephalographic (EEG) activity, signs of toxicity, recovery after challenge and central nervous system histology were examined. The present data demonstrated that atropine/diazepam/pralidoxime alone or combined with gacyclidine did not prevent signs of soman toxicity when treatment was delayed 45 min after poisoning. Atropine/diazepam/pralidoxime also did not control seizures or prevent neuropathology in primates exhibiting severe signs of poisoning when treatment was commenced 30 min after intoxication. However, in this latter case, EEG recordings revealed that additional treatment with gacyclidine was able to stop soman-induced seizures and restore normal EEG activity. This drug also totally prevented the neuropathology observed 5 weeks after soman exposure in animals treated with atropine/diazepam/pralidoxime alone. Overall, in the case of severe OP-poisoning, gacyclidine represents a promising adjuvant therapy to the currently available polymedication to ensure optimal management of organophosphate poisoning in man. This drug is presently being evaluated in a human clinical trial for a different neuroprotective indication. However, it should always be kept in mind that, in the case of severe OP-poisoning, medical intervention must be conducted as early as possible.
Lallement
G
G
Unité de Neuropharmacologie, CRSSA-BP, La Tronche, France. 100437,201@compuserve.com
Clarençon
D
D
Galonnier
M
M
Baubichon
D
D
Burckhart
M F
MF
Peoc'h
M
M
D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D000931:Antidotes / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002531:Cerebellum / Q000187:drug effects / Q000473:pathology; D002540:Cerebral Cortex / Q000187:drug effects / Q000473:pathology; D002619:Chemical Warfare Agents / Q000506:poisoning*; D002801:Cholinesterase Reactivators / Q000627:therapeutic use; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use*; D053138:Cyclohexenes; D003975:Diazepam / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000882:Haplorhini; D008252:Macaca fascicularis; D008297:Male; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D011041:Poisoning / Q000473:pathology; D011220:Pralidoxime Compounds / Q000627:therapeutic use; D012640:Seizures / Q000188:drug therapy; D012999:Soman / Q000506:poisoning*; D013997:Time Factors
D000927:Anticonvulsants; D000931:Antidotes; D002619:Chemical Warfare Agents; D002801:Cholinesterase Reactivators; D003510:Cyclohexanes; D053138:Cyclohexenes; D018691:Excitatory Amino Acid Antagonists; D010880:Piperidines; D011220:Pralidoxime Compounds; D001285:Atropine; C070707:gacyclidine; D012999:Soman; C028797:pralidoxime; D003975:Diazepam